---
title: "Aligos Therapeutics Grants Stock Options to New Employees Under 2024 Inducement Plan"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274312953.md"
datetime: "2026-01-30T13:00:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274312953.md)
  - [en](https://longbridge.com/en/news/274312953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274312953.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274312953.md) | [English](https://longbridge.com/en/news/274312953.md)


# Aligos Therapeutics Grants Stock Options to New Employees Under 2024 Inducement Plan

Aligos Therapeutics Inc. has granted non-qualified stock options to purchase a total of 81,100 shares to newly hired employees, effective January 29, 2026. The options were issued under the company’s 2024 Inducement Plan. Each grant has an exercise price set at the closing price of Aligos’ common stock on the grant date. Vesting will occur over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments, contingent on continued employment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645757-en) on January 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Aligos Therapeutics (ALGS.US)](https://longbridge.com/zh-HK/quote/ALGS.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)

## 相關資訊與研究

- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-HK/news/278565253.md)
- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-HK/news/278776483.md)
- [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/zh-HK/news/278939139.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-HK/news/279032442.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-HK/news/278556054.md)